TITLE: Prescription Drugs and Medicare Financing

CIS-NO: 2001-S361-27  
SOURCE: Committee on Finance. Senate  
DOC-TYPE: Hearing Retrieve the full text of testimony  
DOC-NO: S. Hrg. 107-57  
DATE: Mar. 22, Apr. 24, 2001  
LENGTH: iv+174 p. il.  
CONG-SESS: 107-1  
ITEM-NO: 1038-A; 1038-B  
SUDOC: Y4.F49:S.HRG.107-57  
MC-ENTRY-NO: 2001-15825  
 
GPO-STOCK-NO: 552-070-27125-2.

SUMMARY:
Hearings to examine proposals to establish an outpatient prescription drug benefit for medicare beneficiaries.
 
Supplementary material (p. 87-174) includes witnesses' written statements and written replies to Committee questions.

CONTENT-NOTATION: Medicare prescription drug benefit proposals

DESCRIPTORS:  
    MEDICARE; DRUGS; MEDICAL REGULATION; MANAGED HEALTH CARE; STATISTICAL DATA: HEALTH AND VITAL STATISTICS; STATISTICAL DATA: PUBLIC WELFARE AND SOCIAL SECURITY

01-S361-27 TESTIMONY NO: 1     Mar. 22, 2001 p. 3-32, 105-124, 164-174
 
WITNESSES (and witness notations):
   CRIPPEN, DAN L. (Director, CBO)
   WALKER, DAVID M. (Comptroller General, GAO)
 
STATEMENTS AND DISCUSSION:
   Review of costs associated with including prescription drug coverage in medicare benefits (related tables, graphs, p. 112-120); recommendations for medicare program reform; issues related to proposed medicare prescription drug benefit (related graphs, p. 166-170 passim).
 
CONTENT NOTATION:
   Medicare prescription drug benefit proposals
 
TESTIMONY DESCRIPTORS:
   CONGRESSIONAL BUDGET OFFICE; GENERAL ACCOUNTING OFFICE
 
 
01-S361-27 TESTIMONY NO: 2     Mar. 22, 2001 p. 33-44, 132-141, 146-161
 
WITNESSES (and witness notations):
   FOSTER, RICHARD S. (Chief Actuary, Health Care Financing Administration)
   NEUMAN, PATRICIA (Vice President and Director, Medicare Policy Project, Henry J. Kaiser Family Foundation)
 
STATEMENTS AND DISCUSSION:
   Overview of medicare program financial outlook, including the hospital insurance and supplementary medicare insurance trust fund programs (related graphs, p. 134-140 passim); importance of establishing medicare prescription drug benefits, with related policy recommendations (related graphs, p. 153-159).
 
CONTENT NOTATION:
   Medicare prescription drug benefit proposals
 
TESTIMONY DESCRIPTORS:
   KAISER, HENRY J., FAMILY FOUNDATION; HEALTH CARE FINANCING ADMINISTRATION
 
 
01-S361-27 TESTIMONY NO: 3     Apr. 24, 2001 p. 48-85, 87-105, 141-145
 
WITNESSES (and witness notations):
   COPPOCK, STEVEN M. (Principal, Hewitt Associates, LLC)
   IGNAGNI, KAREN M. (President and CEO, American Association of Health Plans)
   CHOLLET, DEBORAH J. (Senior Fellow, Mathematica Policy Research)
   SCHEPPACH, RAYMOND C. (Executive Director, National Governors' Association)
   CRYSTAL, STEPHEN (Associate Director, Research, Center for State Health Policy, Institute for Health, Health Care Policy, and Aging Research, Rutgers University)
 
STATEMENTS AND DISCUSSION:
   Analysis of medicare beneficiaries outpatient drug coverage under employer-sponsored and other supplemental insurance plans (related graphs, p. 96-104 passim); support for and views on medicare prescription drug benefit proposals; examination of medigap prescription drug coverage policies; elaboration on prescription drug benefit proposals for medicare beneficiaries.
 
CONTENT NOTATION:
   Medicare prescription drug benefit proposals
 
TESTIMONY DESCRIPTORS:
   HEWITT ASSOCIATES, LLC; AMERICAN ASSOCIATION OF HEALTH PLANS; NATIONAL GOVERNORS' ASSOCIATION

LOAD-DATE: November 22, 2002